Company intelligence / Profile preview

ExPLoRNA Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

ExPLoRNA’s proprietary cap analogs have demonstrated significant increases in protein production compared to standard methods, reduced double-stranded RNA formation, and lower IVT costs. The company has received funding from the Bill & Melinda Gates Foundation to further validate these benefits—especially dose reduction—in vaccine and monoclonal antibody settings using state-of-the-art LNP formulations. No direct clinical trial results are published as of May 2025.

Their technology has found commercial application through partnerships with pharmaceutical companies.

Therapeutic areas: OtherImmunologyInfectious Diseases
Modalities: mRNA therapeutics and vaccines (focus on novel cap analogs for improved protein production)Enabling technologies for mRNA drug development and manufacturing
Industry: Chemicals & Materials

Drug pipeline

4 assets

AvantCap AG

Pre-clinical

3 more assets in the full pipeline.

Request access →

Partnerships

Primrose Bio (strategic partnership to co-develop advanced solutions for mRNA medicines combining ExPLoRNA’s capping chemistry with Primrose’s RNA polymerases)

Beyond the preview

Go deeper on ExPLoRNA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExPLoRNA Therapeutics.

Explore the full profile